Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...
Japan’s Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for ...
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly ...
Zacks Investment Research on MSN
REGN soars 41% in six months: Is there more upside potential in 2026?
The going has been strong for Regeneron Pharmaceuticals REGN over the past six months. Shares of this biotech giant have ...
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupix ...
Paris: Sanofi and Regeneron have announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and ...
Johnson & Johnson and Genmab both used the festive period to junk therapies that haven’t lived up to their promise in the ...
Sanofi has announced that Paul Hudson, CEO, will be in attendance at the 44 th annual JP Morgan Healthcare Conference in San ...
Sanofi and Regeneron receives Japanese marketing approval for Dupixent to treat bronchial asthma in children aged 6 to 11 years: Paris Wednesday, December 24, 2025, 11:00 Hrs [IST ...
Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...
Dec 24 (Reuters) - Sanofi (SASY.PA) said on Wednesday it will buy U.S. biotech Dynavax Technologies (DVAX.O) for around $2.2 ...
Regeneron is set for a turnaround as Dupixent and Libtayo drive growth, and 2026 pipeline catalysts may boost revenue. See why REGN stock is a strong buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback